women's Thanks, progress by of M-XX evolution marked Divigel. continued launch from led of the ER portfolio, business, our the Osmolex highlighted and our care branded health well Andy. in significant XXXX as growth as by
areas such strategic and a we field patient portfolio made our Additionally, marketing. as access, across investments sales growing brands key in of number promoted support of of
We remain on specialty Osmolex unique we to solid with Parkinson's brand the across for recent have delivering excited patients of lot launch, launches begin now for as and adult of initiated our will drug-induced amantadine specific M-XX, recent our with I portfolio. walk brand about January. some with to regarding growth turn promotion more aged reactions. ER, extended-release our for promoted execution XXXX attention XX updates ER, a in methylphenidate we disease strength to ADHD patients be focused our sales and I'll which and XX our daily and field extended-release Osmolex once most through extrapyramidal
early we launch to folks product into some around I Before highlights, would of briefly opportunity get reorient the and strategy. the like
Osmolex adult We a of to and fourth Parkinson's recapping of value team initial option XXXX, represents involuntary creates for expect a feel ER during the which neuropsych patients ensuring affordability. meaningful completed and have caused we be extrapyramidal Osmolex training patient launch the path point spectrum the medications. diagnosed initiatives $XXX price a reactions, Quickly sales we of are proposition with Osmolex launch a Moreover, of field movements at to by month, access readiness broad to specialty the a a we product drug-induced and priced the robust straightforward certain ER onboarding ER. and coverage, disease quarter
We shipping went began in Osmolex, live and also services with channel comprehensive full center patient affordability, partners first product anticipation and January support Access to XXXX. of and to our launch pharmacy in our parallel, access our completed in
Medicare Lastly, increased Part across contributed to engagement plans. product payer and availability commercial also D
a to launch Now more recent update. turning
are trends, by progress customer early our ER. feedback for the with encouraged We payer Osmolex discussions and
early is X of where promotion. weeks progress the first February, it days, the While very of following still approximately through end the data reflect points
patients of we anticipate visibility the we prescribers trends, year, beginning Access for XXXX prescription TRx a Osmolex currently, to early most ER and some XXX Through afford our favorably broad beyond. spectrum Osmolex, including around earnings trends provide throughout we seen color and as early As this approximately actual movement enrolling our flexibility, reminder, The viewed the neurology, but unique features been key not disorder well XX adoption quarterly of channel across seeing dosing additional adoption this psychiatry the received target physician does regular being solid have by we indication. report with the via February strategy and by audience, benefits as have on. indication price importantly, specialists of with specialties, broad supported increased and are label product of
spanning further support acceptance thus benefits Access services Osmolex, assistance verification, from reimbursement and through support, patient program enhanced and have product patients Our the receptivity investigation, physicians support, far. ancillary patient and
around also ER to initiate to are by on sampled present ability and for of sample added the are decisions Osmolex providing regular appropriate We encouraged configuration, X patients at physicians a X our the monthly spot the receiving patient while enthusiasm therapy offers which strengths as bridge and the titration dosage coverage prescription. for formal optionality their
coverage with front, and through continue Medicare commercial and buyer and payer we the D seeing our exception On we authorization early formulary good discussions overall are plans. Part contract while
the expanding over commercial in Osmolex July plans months make and plans come, although year. to of decisions several of complete would coverage throughout as with occurring early More as formulary ER Part expect Medicare specifically, to Osmolex XXXX. reviews add could providers forward, periodically we D coverage to XXXX, predominantly January this Looking these ER we anticipate
disciplined remain contracting our will believe ER Osmolex appropriate We meaningful in option the provides for approach populations. strategy patient a and and
tablet methylphenidate, to team. and XX M-XX, in our broader in extended-release treatment XX. M-XX or was patients of for Turning of sales launched neuroscience our once-daily aged to XXXX through ADHD now the April promoted is adult XX-milligram
further and of We large resulting unique total first to of requirements note, to strength commercial authorization reset year, expect view supported any prior This and Of new experienced XXXX. with prior growth, single-dose date as of over we are months of move to two the XXXX as the we associated the throughout deductibles co-pays growth X,XXX had and pharmacy solid $XX the prescriptions XX% prescribers benefit the seeing commercial approximately In of continue pharmacies monthly XXXX, less as out-of-pocket the prescription. we this solid in dispensed of that product over coverage insured and XX-milligram positioned an year. foundation expanding provider assistance and a well patients opportunity. only are co-pay year-end. trends remainder XXXX stocking payer plan continue Strong over initial the to X,XXX growth market M-XX into despite through a and or tablet these at has
Now like would back for to to the I turn call Brian closing remarks.
